Heintges T, Niederau C, Mohr L, Hensel F, Häussinger D
Medizinische Klinik und Poliklinik, Klinik für Gastroenterologie und Infektiologie, Heinrich-Heine-Universität Düsseldorf.
Z Gastroenterol. 1996 Jul;34(7):446-56.
Recent advances in our understanding of viral hepatitis involve the discovery and further characterization of the hepatitis C virus and the interferon treatment of patients with chronic viral hepatitis. Liver cirrhosis and primary hepatocellular carcinoma can develop after some years of disease. Interferon is the only effective treatment, which may improve symptoms and prognosis in some patients. Long-term responses with termination of viral replication are seen in 40% of patients with hepatitis B and 15-25% of patients with hepatitis C. In some patients complete elimination of the virus occurs. Higher response rates are achievable in subgroups of patients with favourable prognostic constellations. Patients have to be informed about side-effects and risks of interferon therapy. Treatment in uncomplicated cases is performed on an outpatient basis. The present paper reviews diagnosis, indications, contraindications and practical considerations concerning interferon treatment in patients with chronic viral hepatitis.
我们对病毒性肝炎认识的最新进展包括丙型肝炎病毒的发现及进一步特性研究,以及慢性病毒性肝炎患者的干扰素治疗。疾病数年之后可能会发展为肝硬化和原发性肝细胞癌。干扰素是唯一有效的治疗方法,在某些患者中可改善症状和预后。40%的乙型肝炎患者和15 - 25%的丙型肝炎患者会出现病毒复制终止的长期反应。在一些患者中,病毒被完全清除。预后良好的患者亚组可实现更高的反应率。必须告知患者干扰素治疗的副作用和风险。非复杂性病例的治疗在门诊进行。本文综述了慢性病毒性肝炎患者干扰素治疗的诊断、适应证、禁忌证及实际注意事项。